← All trials
NCT04693026
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 10, 2020
- Primary completion
- Feb 15, 2021
- Completion date
- Mar 5, 2021
- First posted
- Jan 1, 2021
- Last posted
- Jan 1, 2021
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- M Abdur Rahim Medical College and HospitalLead sponsor
- Jiao Tong UniversityReponsible party - principal investigator
- Jiao Tong UniversityStudy chair
- M Abdur Rahim Medical College and HospitalStudy director
- Jiao Tong UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.